Appia Bio
Tessa Aglupos-McCann has a wealth of work experience, beginning in 2002 as a Senior Associate - General Services at McGladrey & Pullen. In 2004, they moved to Intuit as a Staff Accountant. In 2005, they became Controller at Axxora, LLC. In 2008, they joined Ambrx as an Associate Director of Finance and Senior Accounting Manager. In 2013, they became an Accounting Consultant for Self-Employed. In 2015, they returned to Ambrx as Director of Finance. In 2017, they became an Accounting & Finance Consultant for Self-Employed. In 2018, they moved to SANIFIT as Director of Finance. Most recently, in 2021, they joined Appia Bio as Senior Director of Finance.
Tessa Aglupos-McCann attended San Diego State University from 1999 to 2001, where they earned a Bachelor of Science in Business Administration-Accounting. Tessa also holds a Certified Public Accountant (Inactive) - California certification and a Chartered Global Management Accountant (CGMA) certification.
This person is not in any teams
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).